Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 5/2007

01-05-2007 | Commentary

What is the scale of the future diabetes epidemic, and how certain are we about it?

Authors: S. H. Wild, N. G. Forouhi

Published in: Diabetologia | Issue 5/2007

Login to get access

Excerpt

There is little doubt that worldwide the number of people with diabetes is increasing, and this has led to debate concerning a current or impending epidemic of diabetes [1, 2]. The reasons for the growth in the number of people with diabetes include population growth and ageing (particularly among ethnic groups that are at a higher risk of diabetes than white European populations, such as South Asians, Afro-Caribbeans, Hispanics and native Americans), the improved survival rate of people with diabetes, changes in diagnostic criteria and screening practices, and alarming increases in the prevalence of overweight and obesity. …
Literature
1.
Zimmet P, Lefebvre P (1996) The global NIDDM epidemic. Treating the disease and ignoring the symptom. Diabetologia 39:1247–1248PubMedCrossRef
2.
3.
Mainous AG 3rd, Baker R, Koopman RJ et al (2007) Impact of the population at risk of diabetes on projections of diabetes burden in the United States: an epidemic on the way. Diabetologia, DOI 10.​1007/​s00125-006-0528-5
4.
King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414–1431PubMedCrossRef
5.
Wild S, Roglic G, Green A et al (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047–1053PubMedCrossRef
6.
Boyle JP, Honeycutt AA, Narayan KM et al (2001) Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 24:1936–1940PubMedCrossRef
7.
Narayan KM, Boyle JP, Geiss LS et al (2006) Impact of recent increase in incidence on future diabetes burden: U.S., 2005–2050. Diabetes Care 29:2114–2116PubMedCrossRef
8.
Glumer C, Vistisen D, Borch-Johnsen K et al (2006) Risk scores for type 2 diabetes can be applied in some populations but not all. Diabetes Care 29:410–414PubMedCrossRef
9.
Cowie CC, Rust KF, Byrd-Holt DD et al (2006) Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999–2002. Diabetes Care 29:1263–1268PubMedCrossRef
10.
Tuomilehto J (2007) Counterpoint: evidence-based prevention of type 2 diabetes: the power of lifestyle management. Diabetes Care 30:435–438PubMedCrossRef
11.
Gillies CL, Abrams KR, Lambert PC et al (2007) Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 334:299PubMedCrossRef
12.
Lindstrom J, Ilanne-Parikka P, Peltonen M et al (2006) Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368:1673–1679PubMedCrossRef
13.
Simmons RK, Harding AH, Jakes RW et al (2006) How much might achievement of diabetes prevention behaviour goals reduce the incidence of diabetes if implemented at the population level? Diabetologia 49:905–911PubMedCrossRef
14.
Cherrington AD (2006) 2005 Presidential address: diabetes: past, present, and future. Diabetes Care 29:2158–2164PubMedCrossRef
15.
Gostin LO (2007) Law as a tool to facilitate healthier lifestyles and prevent obesity. JAMA 297:87–90PubMedCrossRef
16.
Lean M, Gruer L, Alberti G et al (2006) ABC of obesity. Obesity—can we turn the tide? BMJ 333:1261–1264PubMedCrossRef
17.
Metadata
Title
What is the scale of the future diabetes epidemic, and how certain are we about it?
Authors
S. H. Wild
N. G. Forouhi
Publication date
01-05-2007
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 5/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-007-0647-7

Other articles of this Issue 5/2007

Diabetologia 5/2007 Go to the issue

Article

Advanced glycation end products cause increased CCN family and extracellular matrix gene expression in the diabetic rodent retina

Letter

Comment on: Evans JMM, Ogston SA, Emslie-Smith A, Morris AD (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930–936

Article

Cortisol clearance and associations with insulin sensitivity, body fat and fatty liver in middle-aged men

Meta-Analysis

Metabolic effects of interventions to increase exercise in adults with type 2 diabetes

Short Communication

Association of glucose levels and glucose variability with mood in type 1 diabetic patients

Article

Prospective prediction of spontaneous but not recurrent autoimmune diabetes in the non-obese diabetic mouse
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits